OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells - PubMed (original) (raw)
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells
P R Rogers et al. Immunity. 2001 Sep.
Free article
Abstract
It is important to understand which molecules are essential for long-lived immunity. We show that OX40 (CD134) is required with CD28 for the survival of CD4 T cells following antigen-driven expansion. In contrast to CD28-/- T cells, which show defects early, OX40-/- T cells are relatively unimpaired in IL-2 production, cell division, and expansion. However, OX40-/- T cells fail to maintain high levels of Bcl-xL and Bcl-2 4-8 days after activation, and undergo apoptosis. Conversely, OX40 stimulation promotes Bcl-xL and Bcl-2 and suppresses apoptosis. Moreover, retroviral transduction of OX40-/- T cells with Bcl-xL or Bcl-2 reverses their survival defect. Thus, a temporal relationship exists between CD28 and OX40, with OX40 being a critical regulator of antigen-driven T cell survival.
Similar articles
- OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.
Huddleston CA, Weinberg AD, Parker DC. Huddleston CA, et al. Eur J Immunol. 2006 May;36(5):1093-103. doi: 10.1002/eji.200535637. Eur J Immunol. 2006. PMID: 16541471 - The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.
Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. Gramaglia I, et al. J Immunol. 2000 Sep 15;165(6):3043-50. doi: 10.4049/jimmunol.165.6.3043. J Immunol. 2000. PMID: 10975814 - Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40.
Walker LS, Gulbranson-Judge A, Flynn S, Brocker T, Lane PJ. Walker LS, et al. Immunol Today. 2000 Jul;21(7):333-7. doi: 10.1016/s0167-5699(00)01636-4. Immunol Today. 2000. PMID: 10871874 Review. - Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells.
Lane P. Lane P. J Exp Med. 2000 Jan 17;191(2):201-6. doi: 10.1084/jem.191.2.201. J Exp Med. 2000. PMID: 10637265 Free PMC article. Review. No abstract available.
Cited by
- Radiation immunodynamics in patients with glioblastoma receiving chemoradiation.
Sloan L, Sen R, Liu C, Doucet M, Blosser L, Katulis L, Kamson DO, Grossman S, Holdhoff M, Redmond KJ, Quon H, Lim M, Eberhart C, Pardoll DM, Hu C, Ganguly S, Kleinberg LR. Sloan L, et al. Front Immunol. 2024 Sep 13;15:1438044. doi: 10.3389/fimmu.2024.1438044. eCollection 2024. Front Immunol. 2024. PMID: 39346903 Free PMC article. - BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
Wang T, Yang Y, Ma L, Feng R, Li J, Zhang C, Bai J, Ding Y, Liu G, Wu F, Lu X, Feng S, Li Z, He T, Li J, Liu H. Wang T, et al. J Immunother Cancer. 2024 Sep 23;12(9):e009476. doi: 10.1136/jitc-2024-009476. J Immunother Cancer. 2024. PMID: 39313307 Free PMC article. - miR-876-3p is a tumor suppressor on 9p21 that is inactivated in melanoma and targets ERK.
Bezrookove V, Khan I, Bhattacharjee A, Fan J, Jones R, Sharma A, Nosrati M, Desprez PY, Salomonis N, Shi Y, Dar A, Kashani-Sabet M. Bezrookove V, et al. J Transl Med. 2024 Aug 13;22(1):758. doi: 10.1186/s12967-024-05527-7. J Transl Med. 2024. PMID: 39138582 Free PMC article. - Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Willoughby JE, Dou L, Bhattacharya S, Jackson H, Seestaller-Wehr L, Kilian D, Bover L, Voo KS, Cox KL, Murray T, John M, Shi H, Bojczuk P, Jing J, Niederer H, Shepherd AJ, Hook L, Hopley S, Inzhelevskaya T, Penfold CA, Mockridge CI, English V, Brett SJ, Srinivasan R, Hopson C, Smothers J, Hoos A, Paul E, Martin SL, Morley PJ, Yanamandra N, Cragg MS. Willoughby JE, et al. J Immunother Cancer. 2024 Jul 4;12(7):e008677. doi: 10.1136/jitc-2023-008677. J Immunother Cancer. 2024. PMID: 38964788 Free PMC article. - PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
Ouyang W, Jin SW, Xu N, Liu WY, Zhao H, Zhang L, Kang L, Tao Y, Liu Y, Wang Y, Wang J, Liu F, Yu L, Liu Z, Mi JQ. Ouyang W, et al. J Immunother Cancer. 2024 Apr 8;12(4):e008429. doi: 10.1136/jitc-2023-008429. J Immunother Cancer. 2024. PMID: 38589248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials